U.S. markets closed
  • S&P Futures

    4,012.25
    +9.00 (+0.22%)
     
  • Dow Futures

    34,058.00
    +72.00 (+0.21%)
     
  • Nasdaq Futures

    11,836.50
    +30.75 (+0.26%)
     
  • Russell 2000 Futures

    1,846.10
    +4.20 (+0.23%)
     
  • Crude Oil

    77.55
    +0.62 (+0.81%)
     
  • Gold

    1,785.70
    +4.40 (+0.25%)
     
  • Silver

    22.59
    +0.18 (+0.79%)
     
  • EUR/USD

    1.0515
    +0.0018 (+0.17%)
     
  • 10-Yr Bond

    3.5990
    +0.0930 (+2.65%)
     
  • Vix

    20.75
    +1.69 (+8.87%)
     
  • GBP/USD

    1.2210
    +0.0016 (+0.13%)
     
  • USD/JPY

    136.4940
    -0.1910 (-0.14%)
     
  • BTC-USD

    17,043.55
    -218.38 (-1.27%)
     
  • CMC Crypto 200

    402.80
    -8.42 (-2.05%)
     
  • FTSE 100

    7,567.54
    +11.31 (+0.15%)
     
  • Nikkei 225

    27,856.82
    +36.42 (+0.13%)
     

Lumos Pharma to Participate in the Jefferies 2020 Healthcare Conference

AUSTIN, Texas, May 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced that the company will present at the virtual Jefferies 2020 Healthcare Conference on Tuesday, June 2, 2020, at 4:30PM ET. Throughout that same day, Lumos Pharma management will also participate in one-on-one calls with investors. Please contact your Jefferies sales representative to schedule a one-on-one call with our management team.

A live webcast of the presentation will be available on the Company’s website in the “Investors & Media” section under “Events and Presentations.” Listeners may also access the webcast through the following link: http://wsw.com/webcast/jeff126/lumo/. An archived edition of the presentation will be available on the Company’s website later in the day.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding by leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit www.lumos-pharma.com.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-648-3757
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.